CHIMERIC THERAPEUTICS LIMITED — Director's Dealing 2023

Jul 16, 2023

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

	Chimeric Therapeutics Limited (ASX: CHM)
Name of Entity:
	68 638 835 828
ABN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Paul Hopper
Date of Last Notice:	30 March 2022

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

director” should be disclosed in this part.
Direct or Indirect Interest		Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		Director related entity
Date of change		12 July 2023
No. of securities held prior to change				Options - 2,941,176 2,941,176
			Shares	Options
		Direct	375,000	-
		Indirect	80,718,954	2,941,176
		Total	81,093,954	2,941,176
Class		Fully Paid Ordinary Shares
Number acquired				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	13,043,478	-
		Total	13,043,078	-
Number disposed				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		Total	-	-

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		$0.046 per share.	$0.046 per share.
No. of securities held after change				Options - 2,941,176 2,941,176
			Shares	Options
		Direct	375,000	-
		Indirect	93,762,032	2,941,176
		Total	94,137,432	2,941,176
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		Participation in Board & Management placement announced 15 May 2023.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 3 – Closed period

Were the interests in the securities or No contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided?

==> picture [39 x 23] intentionally omitted <==

The CFO Solution

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

ntroduced 30/9/2001. Ame	nded 01/01/11
	Chimeric Therapeutics Limited (ASX: CHM)
Name of Entity:
	68 638 835 828
ABN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Cindy Elkins
Date of Last Notice:	30 March 2022

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Direct or Indirect Interest		Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		-
Date of change		12 July 2023
No. of securities held prior to change				Options 2,750,000 7,873 2,757,873
			Shares	Options
		Direct	-	2,750,000
		Indirect	32,673	7,873
		Total	32,673	2,757,873
Class		Fully Paid Ordinary Shares
Number acquired				Options - - -
			Shares	Options
		Direct	108,695	-
		Indirect	-	-
		Total	108,695	-
Number disposed				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		Total	-	-

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		$0.046 per share.	$0.046 per share.
No. of securities held after change				Options 2,750,000 7,873 2,757,873
			Shares	Options
		Direct	108,695	2,750,000
		Indirect	32,673	7,873
		Total	141,368	2,757,873
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		Participation in Board & Management placement announced 15 May 2023.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or No contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided?

==> picture [39 x 23] intentionally omitted <==

The CFO Solution

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

	Chimeric Therapeutics Limited (ASX: CHM)
Name of Entity:
	68 638 835 828
ABN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Dr George Matcham
Date of Last Notice:	7 July 2022

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Direct or Indirect Interest		Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		N/A
Date of change		12 July 2023
No. of securities held prior to change				Options 2,750,000 158,730 2,908,730
			Shares	Options
		Direct	-	2,750,000
		Indirect	1,000,800	158,730
		Total	1,000,800	2,908,730
Class		Fully Paid Ordinary Shares
Number acquired				Options - - -
			Shares	Options
		Direct	1,086,956	-
		Indirect	-	-
		Total	1,086,956	-

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number disposed				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		Total	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		$0.046 per share.
No. of securities held after change				Options 2,750,000 158,730 2,908,730
			Shares	Options
		Direct	1,086,956	2,750,000
		Indirect	1,000,800	158,730
		Total	2,087,756	2,908,730
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		Participation in Board & Management placement announced 15 May 2023.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

art 3 – Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	No

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

If prior written clearance was provided, on what date was this provided?	No

==> picture [38 x 24] intentionally omitted <==

The CFO Solution

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

kayoRule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

	Chimeric Therapeutics Limited (ASX: CHM)
Name of Entity:
	68 638 835 828
ABN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Jennifer Chow
Date of Last Notice:	15 December 2022

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Direct or Indirect Interest		Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		-
Date of change		12 July 2023
No. of securities held prior to change				Options 27,513,863 - 27,513,863
			Shares	Options
		Direct	1,702,914	27,513,863
		Indirect	7,639,315	-
		Total	9,342,229	27,513,863
Class		Fully Paid Ordinary Shares
Number acquired				Options - - -
			Shares	Options
		Direct	108,695	-
		Indirect	-	-
		Total	108,695	-
Number disposed				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		Total	-	-

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		$0.046 per share.	$0.046 per share.
No. of securities held after change				Options 27,513,863 - 27,513,863
			Shares	Options
		Direct	1,811,609	27,513,863
		Indirect	7,639,315	-
		Total	9,450,924	27,513,863
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		Participation in Board & Management placement announced 15 May 2023.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or No contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided?

==> picture [39 x 23] intentionally omitted <==

The CFO Solution

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

ntroduced 30/9/2001. Ame	nded 01/01/11
	Chimeric Therapeutics Limited (ASX: CHM)
Name of Entity:
	68 638 835 828
ABN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Leslie Chong
Date of Last Notice:	30 June 2022

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Direct or Indirect Interest		Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		-
Date of change		12 July 2023
No. of securities held prior to change				Options 2,753,905 - 2,753,905
			Shares	Options
		Direct	46,205	2,753,905
		Indirect	-	-
		Total	46,205	2,753,905
Class		Fully Paid Ordinary Shares
Number acquired				Options - - -
			Shares	Options
		Direct	108,695	-
		Indirect	-	-
		Total	108,695	-
Number disposed				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		Total	-	-

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		$0.046 per share.	$0.046 per share.
No. of securities held after change				Options 2,753,905 - 2,753,905
			Shares	Options
		Direct	154,900	2,753,905
		Indirect	-	-
		Total	154,900	2,753,905
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		Participation in Board & Management placement announced 15 May 2023.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or No contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided?

==> picture [39 x 23] intentionally omitted <==

The CFO Solution

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

ntroduced 30/9/2001. Ame	nded 01/01/11
	Chimeric Therapeutics Limited (ASX: CHM)
Name of Entity:
	68 638 835 828
ABN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Lesley Russell
Date of Last Notice:	19 January 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Direct or Indirect Interest		Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		N/A
Date of change		12 July 2023
No. of securities held prior to change				Options 2,750,000 - 2,750,000
			Shares	Options
		Direct	-	2,750,000
		Indirect	-	-
		Total	-	2,750,000
Class		Fully Paid Ordinary Shares
Number acquired				Options - - -
			Shares	Options
		Direct	1,739,130	-
		Indirect	-	-
		Total	1,739,130	-
Number disposed				Options - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		Total	-	-

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		$0.046 per share.	$0.046 per share.
No. of securities held after change				Options 2,750,000 - 2,750,000
			Shares	Options
		Direct	1,739,130	2,750,000
		Indirect	-	-
		Total	1,739,130	2,750,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		Participation in Board & Management placement announced 15 May 2023.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or No contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided?

==> picture [39 x 23] intentionally omitted <==

The CFO Solution

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011